Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen
Retrieved on:
Monday, September 18, 2023
CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded its intellectual property rights with a new patent family.
Key Points:
- CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded its intellectual property rights with a new patent family.
- Expanded arbaclofen rights with a newly filed patent family and with exclusive rights in all indications, incl.
- Allos also announces today the worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including Autism Spectrum Disorder.
- Dr. Randall Carpenter, MD, co-founder of Allos Pharma Inc